



## Final Appraisal Recommendation

Advice No: 3912 – November 2012

### Insulin detemir (Levemir®) 100 U/ml solution for injection

Limited submission by Novo Nordisk Ltd

#### Recommendation of AWMSG

Insulin detemir (Levemir®) is recommended as an option for use within NHS Wales for the treatment of diabetes mellitus in children aged 1–5 years.

#### Additional notes:

- AWMSG is of the opinion that insulin detemir (Levemir®) may be appropriate for use within NHS Wales prescribed under specialist recommendation for the indication under consideration.
- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Novo Nordisk Ltd
Date of first issue	November 2012
Last reviewed	November 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3912:  
Insulin detemir (Levemir®) 100 U/ml solution for injection. November 2012.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).